How will Ingrezza and Austedo compete in the Tardive Dyskinesia Market?
By 2025, the market for tardive dyskinesia (TD) treatments is expected to see continued competition between Lundbeck's Ingrezza (valbenazine) and Teva's Austedo (deutetrabenazine) [1]. Both medications target the underlying causes of TD, a neurological disorder characterized by involuntary movements, and have established themselves as significant treatment options [2].
What is Tardive Dyskinesia and How are Ingrezza and Austedo Treated?
Tardive dyskinesia is a side effect of long-term use of dopamine-blocking medications, often used to treat psychiatric conditions [3]. Ingrezza and Austedo work differently to manage these involuntary movements. Ingrezza is a selective VMAT2 inhibitor that targets VMAT2, a protein involved in the storage and transport of neurotransmitters like dopamine in the brain [1][4]. Austedo is also a VMAT2 inhibitor, but it uses deuterium, a stable isotope of hydrogen, to alter the drug's metabolism, leading to a longer duration of action [5].
When Does Ingrezza or Austedo Patent Exclusivity Expire?
Information regarding patent expiry for Ingrezza and Austedo is not readily available in the provided text. DrugPatentWatch.com is a resource that tracks drug patents and exclusivity [6].
How Do Ingrezza and Austedo Compare in Effectiveness and Side Effects?
Clinical trials have demonstrated the efficacy of both Ingrezza and Austedo in reducing the severity of tardive dyskinesia. While both drugs are generally well-tolerated, they do have different side effect profiles. Common side effects reported for Ingrezza include somnolence and nasopharyngitis [4]. Austedo's prescribing information highlights the potential for depression, anxiety, and suicidal ideation, particularly in patients with Huntington's disease [5].
What is the Current Market Share of Ingrezza vs. Austedo?
Specific market share data for Ingrezza versus Austedo in 2025 is not provided. However, both drugs have achieved significant market penetration since their respective approvals [1][4][5].
What Are the Next Steps for These TD Treatments?
Ongoing research and clinical trials may further refine the understanding of these medications' roles in TD management. Future developments could include exploring their use in different patient populations or in combination with other therapies.
Sources
[1] Lundbeck. (n.d.). Ingrezza. Retrieved from https://www.lundbeck.com/global/our-therapies/ingrezza
[2] DrugPatentWatch.com. (n.d.). Tardive Dyskinesia Market. Retrieved from https://www.drugpatentwatch.com/
[3] National Institute of Neurological Disorders and Stroke. (n.d.). Tardive Dyskinesia Information Page. Retrieved from https://www.ninds.nih.gov/
[4] Teva Pharmaceutical Industries Ltd. (n.d.). Austedo. Retrieved from https://www.tevapharm.com/our-products/
[5] U.S. Food & Drug Administration. (n.d.). FDA Drug Approvals. Retrieved from https://www.fda.gov/drugs/new-drugs-fda-approvals
[6] DrugPatentWatch.com. (n.d.). Patent Search. Retrieved from https://www.drugpatentwatch.com/patents/search